A Study to Assess the Efficacy of Skin Rejuvenation Therapy in Combination With Neurotoxin and Full Facial Filler Treatments

Inclusion Criteria:

- Subject requires a full facial rejuvenation with a HA soft tissue filler and/or
botulinum neurotoxin, per judgment of the PI;

- Subject is willing and able to provide written informed consent prior to the
performance of any study related procedure;

- Subject is willing and able to comply with the protocol requirements; and

- Subject is willing and able to provide written photo consent and adhere to the
photography and video procedures such as removal of jewelry and makeup.

Exclusion Criteria:

- Subjects who have received any facial filler or neurotoxin treatments in the 12-month
period prior to enrollment;

- Previous treatment with any facial aesthetic procedure (e.g. chemical peeling, photo
rejuvenation, and laser treatments) within the 12-month period prior to enrollment;

- Subjects who plan to undergo facial cosmetic surgery or any aesthetic procedure (e.g.
neurotoxins, dermal fillers, laser treatments, and chemical peels), which are not
specified in this protocol, during the course of the study;

- A known allergy or sensitivity to any component of the study ingredients;

- Use of systemic steroids or anticoagulation medications;

- Subjects with a history of bleeding disorders;

- Subjects with severe allergies manifested by a history of anaphylaxis or presence of
multiple severe allergies;

- Subjects with hypersensitivity to botulinum neurotoxin;

- Subject with allergies to gram positive bacterial proteins;

- Sensitivity to sulfides;

- Subjects with allergy to cow's milk protein;

- Subjects with previous history of sensitivity to amide type local anesthetics;

- Subject with surgical alterations to the facial anatomy or marked facial asymmetry;

- Inflammation or infection at the injection site(s);

- Subjects with a history of eyelid or eyebrow ptosis;

- Excessive dermatochalasis, deep dermal scarring, or thick sebaceous skin;

- Subjects with neuromuscular disorders;

- Use of anticholinergic, aminoglycosides or other agents that interfere with
neuromuscular transmission (e.g., curare-like agents), or muscle relaxants;

- Subjects with immunodeficiencies such as HIV, lupus, scleroderma, and systemic
infections;

- Pregnant, nursing, or sexually active female subjects who are of childbearing
potential and who are not willing to use an acceptable form of contraception (e.g.,
barrier methods used with a spermicidal agent, hormonal methods, IUD, surgical
sterilization, abstinence);

- Current history of chronic drug or alcohol abuse;

- Concurrent therapy that, in the investigator's opinion, would interfere with the
evaluation of the safety or efficacy of the study product;

- Subjects who, in the investigator's opinion, have a history of poor cooperation,
non-compliance with medical treatment, or unreliability; and

- Enrollment in any active study involving the use of investigational devices or drugs.